Novavax Leaps on Vaccine Trials

Chinese vaccine shows promise

Nucleus Network has begun the Phase 1/2 COVID-19 vaccine trial in Australia on behalf of Novavax, Inc., the developer of NVX-CoV2373 and sponsor of the trial, with funding support from the Norway-based Coalition for Epidemic Preparedness Innovations (CEPI), joining the global response to this pandemic.

In these people, "their immune systems will essentially rear up and blunt the effect of the vaccine", said Kirsten Lyke, a vaccinologist at the University of Maryland who is leading another COVID-19 vaccine trial. Two doses of the vaccine will be administered, both with and without the enhancing agent. After 28 days, most participants had a significant increase in binding antibodies. If proven effective, the trials will be expanded to the U.S.

Novavax is developing the SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine - NVX-CoV2373. The most common adverse reactions were mild pain at the injection site in 54 per cent (58/108) of the recipients, fever (46 per cent, 50/108), fatigue (44 per cent, 47/108), headache (39 per cent, 42/108) and muscle pain (17 per cent, 18/108).

Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for the COVID-19 coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.

Earlier this week, AstraZeneca received a boost in its efforts after the USA pledged as much as $1.2 billion towards development of the vaccine and said it would order 300 million doses.

If the vaccine works, researchers hope 100 million doses can be made by the end of this year and 1.5 billion next year.

He added that should this or any other vaccine prove to be a success, it would most likely be delivered via a risk-based approach.

Over 120 vaccines have been proposed across the world including in India.

The researchers noted that people who have already developed a high immunity to the adenovirus had a less positive antibody and T-cell response to the vaccine.

Novavax said the first phase of its trial would be randomized, observer blind and placebo controlled. The firm said it is collaborating with a number of countries and multilateral organizations in a bid to make the vaccine "widely accessible around the world in an equitable manner".

Meanwhile, another vaccine is already approved for human testing in Canada, with trials set to begin next week.

"We are still a long way from this vaccine being available to all", Wei Chen from the Beijing Institute of Biotechnology said Friday in a release.

"This project is for the human race, not just Thais. They change lives", Glenn said.



Latest news

National Hockey League regular season officially over; Wild makes postseason
The top four on each side will play a round-robin against each of the others to determine the order of the top seeds . Of course, the Bruins could just win the tournament outright and avoid worrying about a drop in seeding.

Mercedes-Benz E-class Coupe, Cabriolet facelifts revealed
The E53 Coupe is capable of doing the 0-100 kmph run in just 4.4 seconds which is 0.2 seconds quciker than the E53 Cabriolet. Mercedes hasn't released fuel-economy figures but says this engine will be more efficient than the twin-turbo V-6.

Kyoto Animation comments on suspect's arrest
Media reports at the time said Aoba told police he had taken the action because the studio had plagiarized his novel. Many others tried but failed to escape to the roof, fire officials said and many died of carbon monoxide poisoning .

Tropical Storm Bertha forms near SC
The National Hurricane Center says the second named storm of the season, Tropical Storm Bertha , has formed off the SC coast. Up to one inch of rain has already fallen with an additional 1 to 2 inches expected during the next few hours.

Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate Reuters
For the first time, this will include participants over 60 years old, an important target population for the vaccine. App to help enrol COVID-19 patients into clinical trials developed ...

Other news